Brenton Taylor Sells 5,000 Shares of Inogen Inc (INGN) Stock

Inogen Inc (NASDAQ:INGN) EVP Brenton Taylor sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $130.76, for a total transaction of $653,800.00. Following the completion of the transaction, the executive vice president now owns 38,982 shares in the company, valued at $5,097,286.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Brenton Taylor also recently made the following trade(s):

  • On Friday, February 16th, Brenton Taylor sold 5,000 shares of Inogen stock. The shares were sold at an average price of $125.06, for a total transaction of $625,300.00.
  • On Wednesday, February 14th, Brenton Taylor sold 15,000 shares of Inogen stock. The shares were sold at an average price of $117.47, for a total transaction of $1,762,050.00.

Shares of Inogen Inc (INGN) opened at $131.15 on Friday. The firm has a market cap of $2,737.10, a price-to-earnings ratio of 106.63, a price-to-earnings-growth ratio of 4.27 and a beta of 1.02. Inogen Inc has a twelve month low of $67.34 and a twelve month high of $132.68.

INGN has been the topic of several analyst reports. Leerink Swann restated an “outperform” rating and issued a $120.00 price objective (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. BidaskClub lowered shares of Inogen from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective on the stock in a report on Thursday, November 9th. Needham & Company LLC increased their price objective on shares of Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a report on Wednesday, November 8th. Finally, Piper Jaffray Companies upgraded shares of Inogen from a “neutral” rating to an “overweight” rating in a report on Tuesday, February 20th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Inogen presently has an average rating of “Buy” and a consensus target price of $103.71.

Institutional investors and hedge funds have recently bought and sold shares of the business. Lenox Wealth Advisors Inc. acquired a new stake in Inogen in the fourth quarter worth $100,000. Steward Partners Investment Advisory LLC raised its holdings in Inogen by 1,000.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after purchasing an additional 1,000 shares during the period. Simplex Trading LLC acquired a new stake in Inogen in the fourth quarter worth $153,000. Ameritas Investment Partners Inc. raised its holdings in Inogen by 6.1% in the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 86 shares during the period. Finally, LS Investment Advisors LLC raised its holdings in Inogen by 138.6% in the fourth quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock worth $180,000 after purchasing an additional 880 shares during the period.

ILLEGAL ACTIVITY WARNING: “Brenton Taylor Sells 5,000 Shares of Inogen Inc (INGN) Stock” was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/25/brenton-taylor-sells-5000-shares-of-inogen-inc-ingn-stock-2.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply